Avsola Alternatives Compared
| Avsola (infliximab) | Otezla (apremilast) | Adalimumab |
|
|---|
| Avsola (infliximab) | Otezla (apremilast) | Adalimumab |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Ankylosing Spondylitis, Crohn's Disease, Ulcerative Colitis, Crohn's Disease - Active, Inflammatory Bowel Disease, Plaque Psoriasis, Psoriasis, Psoriatic Arthritis, Rheumatoid... View more |
Prescription only
Otezla is a PDE4 inhibitor that may be used to treat adults with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s Disease. It may also be used to treat plaque psoriasis... View more |
Prescription only
Adalimumab is a TNF-alfa inhibitor that may be used to treat a wide range of different inflammatory conditions, such as rheumatoid Arthritis, psoriasis, ankylosing spondylitis, Crohn's disease, and... View more |
||||||||||||||||||||||||
| More about Avsola (infliximab) | More about Otezla (apremilast) | More about Adalimumab | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Avsola has an average rating of 6.6 out of 10 from a total of 9 ratings on Drugs.com. 44% of reviewers reported a positive effect, while 22% reported a negative effect. |
Otezla has an average rating of 5.2 out of 10 from a total of 439 ratings on Drugs.com. 35% of reviewers reported a positive effect, while 40% reported a negative effect. |
Adalimumab has an average rating of 6.4 out of 10 from a total of 725 ratings on Drugs.com. 55% of reviewers reported a positive effect, while 31% reported a negative effect. |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Side Effects | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
N/A |
Lower cost generic |
|||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Avsola prices |
View all Otezla prices |
View all Adalimumab prices |
||||||||||||||||||||||||
| Dosage Forms Available | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Other infliximab brands include: Inflectra, Ixifi, Remicade, Renflexis, Zymfentra |
N/A |
Abrilada, Amjevita, Cyltezo, Hadlima, Hulio, Humira, Hyrimoz, Idacio, Simlandi, Yuflyma, Yusimry View more | ||||||||||||||||||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||||||||||
|
228 hours |
9 hours |
480 hours |
||||||||||||||||||||||||
| CSA Schedule ** View glossary of terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 560 drugs are known to interact with Avsola:
|
A total of 102 drugs are known to interact with Otezla:
|
A total of 542 drugs are known to interact with Adalimumab:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
N/A |
March 21, 2014 |
N/A |
||||||||||||||||||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.